Molecular Pathology/Molecular Diagnostics/Genetic Testing | UHC Coverage Update

TL;DR: UnitedHealthcare modified its molecular pathology, molecular diagnostics, and genetic testing coverage policy for Medicare Advantage members, effective January 5, 2026. Here's what billing teams need to do.

UnitedHealthcare updated policy code molecular-pathology-diagnostics-genetic-testing to reflect current coverage criteria across more than 108 CPT codes. This includes codes for oncology panels, hereditary condition testing, and NGS-based assays — from CPT 81170 (ABL1) to 81519 (Oncotype DX breast) to 0315U (cutaneous squamous cell carcinoma). If your lab or practice bills genetic testing for Medicare Advantage members, this coverage policy change touches nearly every category of molecular diagnostics you run.

Quick-Reference Table

UnitedHealthcare Genetic Testing Coverage Criteria and Medical Necessity Requirements 2026

The UnitedHealthcare genetic testing coverage policy sets medical necessity criteria at the individual gene, panel, and clinical indication level. That's not unusual for molecular pathology — but the scope here is large. Coverage depends on diagnosis, clinical presentation, and in many cases, the specific testing technology used.

The policy draws a clear line between NCD coverage and LCD coverage. For NGS-based tests, CMS NCD 90.2 governs somatic and germline cancer testing. For RNA sequencing and protein analysis using NGS, Medicare Administrative Contractors (MACs) make the call. If your MAC has a local coverage determination (LCD) for a specific molecular test, that LCD controls — not just the covered indications in this policy.

That's the piece billing teams miss most often. UnitedHealthcare's Medicare Advantage coverage policy defers to active LCDs where they exist. Before you assume a test is covered based on the indications list below, check whether your jurisdiction has a relevant LCD. If it does, you must meet those LCD criteria and document accordingly.

Medical necessity for specific covered tests requires:

Prior authorization requirements are not uniformly specified in this policy for every code. However, given the high-dollar nature of NGS panels and proprietary assays (like Oncotype DX or BDX-XL2), check prior auth requirements at the claim level before submission. Missing prior authorization on a high-cost molecular assay is one of the most common — and most expensive — claim denial scenarios in genetic testing billing.

UnitedHealthcare Genetic Testing Exclusions and Non-Covered Indications

Laboratory developed tests (LDTs) without FDA approval or clearance carry elevated scrutiny under this policy. The policy defines an LDT as any test developed by a laboratory without FDA approval or clearance. That definition matters because many proprietary assays — including some listed here under "Provisional Coverage" — fall into this category.

Tests listed under Provisional Coverage are not fully covered indications. They're covered provisionally, which means conditions apply. Treat these differently in your billing workflow. If you're billing 0018U (thyroid microRNA profiling), 0026U (thyroid DNA/mRNA NGS), or 0080U (lung mass spectrometric analysis), verify that provisional coverage criteria are met before submitting.

The policy also flags that tests covered under NCD 90.2 follow CMS rules — UHC Medicare Advantage is bound by those same NCD criteria. If the NCD excludes a specific use case, this policy does not expand coverage for it.

Coverage Indications at a Glance

UnitedHealthcare Molecular Diagnostics Billing Guidelines and Action Items 2026

CPT, HCPCS, and ICD-10 Codes for Molecular Pathology/Molecular Diagnostics/Genetic Testing Under molecular-pathology-diagnostics-genetic-testing

Covered CPT Codes (When Medical Necessity Criteria Are Met)

Provisional Coverage CPT/Proprietary Codes (Additional Documentation Required)

Deleted Codes (Do Not Bill)